Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Wegovy approved to prevent heart problems or strokes in obese and overweight adults

Wegovy approved to prevent heart problems or strokes in obese and overweight adults
FILE PHOTO: A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. Wegovy's high price and the huge increase in people taking it has employers reconsidering when and how to reimburse use of such treatments to prevent a steep spike in health insurance costs, industry experts say REUTERS/Jim Vondruska/Illustration/File Photo

A post-approval clinical study showed that Wegovy significantly reduced the risk of major adverse cardiovascular events by 20% compared to a placebo

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication of semaglutide (Wegovy), authorising its use to reduce the risk of serious heart problems and strokes in adults who are obese or overweight.


Semaglutide, a GLP-1 receptor agonist, was previously approved for use in the treatment of obesity and weight management, to be used alongside diet, physical activity and behavioural support.

The latest approval establishes it as the first weight loss drug to be prescribed to prevent cardiovascular events, such as cardiovascular death, non-fatal heart attack and non-fatal stroke, in people with established cardiovascular disease and a Body Mass Index (BMI) higher or equal to 27 kg/m2.

Novo Nordisk, the manufacturer of Wegovy, received this authorisation on 23 July following compelling evidence from a recent post-approval clinical study involving over 17,600 participants.

The study demonstrated that Wegovy, administered at a dose of 2.4 mg once weekly via subcutaneous injection for up to five years, significantly lowers the incidence of major adverse cardiovascular events (MACE) by 20 per cent compared to a placebo.

Specifically, 6.5 per cent of participants receiving Wegovy experienced cardiovascular events such as cardiovascular death, heart attack and stroke, compared to 8 per cent of those on the placebo.

Shirley Hopper, MHRA Deputy Director of Innovative Medicines, confirmed that the appropriate regulatory standards of safety, quality and effectiveness for the approval of this medicine have been met.

Hopper described this new treatment option as an “important step forward in tackling the serious health consequences of obesity.”

Professor Bryan Williams, Chief Scientific and Medical Officer at the British Heart Foundation, highlighted that several recent studies have shown semaglutide’s effectiveness in improving the quality of life for those with cardiovascular disease, including by lowering the risk of serious cardiac events.

Semaglutide works by mimicking the action of the GLP-1 hormone, which is involved in regulating blood sugar levels. It binds to GLP-1 receptors on pancreatic cells, enhancing insulin secretion in response to meals, reducing glucagon release, and slowing the gastric emptying process, thereby promoting weight loss.

The treatment is taken as a solution for injection in a pre-filled pen.

The MHRA noted the most common side effects of the medicine are gastrointestinal disorders including nausea, diarrhoea, constipation and vomiting.

Professor Williams stated that that nearly two-thirds of adults in England are living with excess weight or obesity.

He cautioned that those with existing cardiovascular disease have a very high risk of developing a severe event such as a heart attack or stroke.

Cardiovascular disease (CVD) refers to a range of conditions that affect the heart and blood vessels.

It is commonly linked to the build-up of fatty deposits inside the arteries (atherosclerosis) and an increased risk of blood clots.

In the UK, CVD is a leading cause of death and disability, but it can often be prevented through a healthy lifestyle.

More For You

Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Primary care leaders join forces in effort to 'transform investment into primary care'

Community Pharmacy England (CPE) has teamed up with other national primary care bodies to urge the government to allocate more funds towards the sector.

In a joint statement released on the back of the government’s spending review, last week, the organisations welcomed the government’s continued determination to ‘shift care from hospitals to community and from sickness to prevention’ but warned that this would not be possible ‘without further investment in primary care’.

Keep ReadingShow less
Cancer patients warned against using weight-loss jabs

Macmillan Cancer Support said there is not enough evidence on how the weight-loss jabs might affect anti-cancer treatments.

iStock

Cancer patients warned against using weight-loss jabs

Cancer patients have been advised to consult their doctor before taking any weight-loss jabs.

Macmillan Cancer Support has issued this advisory following a surge in calls by cancer patients asking whether they can take fat loss jabs such as Wegovy and Mounjaro.

Keep ReadingShow less
Kamson Pharmacy to deliver more clinical services after installing hub and spoke technology

The FLOWRx auto hub in the new Kamson warehouse in Uckfield.

Kamson Pharmacy to deliver more clinical services after installing hub and spoke technology


Kamsons Pharmacy has announced that it has implemented a state-of-the-art hub and spoke dispensing model with the aim of freeing up more time to deliver clinical services.

Keep ReadingShow less
RPS group aims to tackle barriers holding back black pharmacy students

Work is underway to improve inclusivity in teaching

Pic credit: iStock

RPS group aims to tackle barriers holding back black pharmacy students

A cross-sector group aimed at tackling barriers that block the progression of black students and trainee pharmacists held its first meeting this week.

The Royal Pharmaceutical Society (RPS) has created the Differential Attainment Oversight Group to address issues that black or black British African student pharmacists and foundation trainees face such as limited access to work experience, financial support and visible role models in education and training.

Keep ReadingShow less
Older adult organizing medicine bottles in a cool, dry storage area during warm weather.

People are being advised to keep medicine below 25° C

Pic credit: iStock

Pharmacies advise patients on storing medicines safely during heatwave

Patients are being given important advice and guidance on the impact heat can have on their medicine and where to keep different medicines as the UK goes through a heatwave.

People are being advised to keep medicine below 25° C if they are able to, unless storage instructions state it needs to be kept at an alternative temperature, such as drugs that need to be refrigerated.

Keep ReadingShow less